文献速递类风湿关节炎

韩国类风湿关节炎患者使用托珠单抗与肿瘤坏死因子抑制剂的严重感染风险比较

The risk of serious infection in rheumatoid arthritis patients receiving tocilizumab compared with tumor necrosis factor inhibitors in Korea.
PubMed 文献 · Semin Arthritis Rheum · 2021-07-08

该回顾性队列研究利用韩国国民健康保险数据,纳入2013年1月至2018年6月启动托珠单抗或肿瘤坏死因子抑制剂(TNFi)治疗的≥18岁类风湿关节炎(RA)患者,共8794例(托珠单抗1395例,TNFi 7399例)。经逆概率治疗加权(IPTW)和多变量Cox回归调整后,托珠单抗与TNFi相比严重感染(SI)风险无显著差异(HR 1.00,95%CI 0.90-1.11),但托珠单抗与较高的皮肤和皮下组织感染风险(HR 1.26,95%CI 1.02-1.54)及较低的泌尿生殖系统感染风险(HR 0.65,95%CI 0.49-0.87)相关。

要点

  • 托珠单抗与TNFi相比严重感染风险无显著差异(HR 1.00,95%CI 0.90-1.11)。
  • 托珠单抗与较高的皮肤和皮下组织感染风险相关(HR 1.26,95%CI 1.02-1.54)。
  • 托珠单抗与较低的泌尿生殖系统感染风险相关(HR 0.65,95%CI 0.49-0.87)。

核心结论

  • 在韩国RA患者中,托珠单抗与TNFi相比不增加严重感染风险。
  • 但托珠单抗应谨慎用于皮肤感染高危患者。

研究设计与样本

  • 回顾性队列研究,使用韩国国民健康保险数据。
  • 纳入≥18岁RA患者,2013年1月至2018年6月启动托珠单抗或TNFi治疗。
  • 共8794例患者,托珠单抗1395例,TNFi 7399例。
  • 采用IPTW倾向评分加权和多变量Cox回归模型估计HR。

主要发现

  • 托珠单抗组平均随访1.2年,TNFi组平均随访1.0年。
  • 经IPTW和调整后,托珠单抗与TNFi相比严重感染风险无显著差异(HR 1.00,95%CI 0.90-1.11)。
  • 托珠单抗与较高的皮肤和皮下组织感染风险相关(HR 1.26,95%CI 1.02-1.54)。
  • 托珠单抗与较低的泌尿生殖系统感染风险相关(HR 0.65,95%CI 0.49-0.87)。

临床怎么用

  • 在RA患者中,托珠单抗的严重感染风险与TNFi相当。
  • 使用托珠单抗时需关注皮肤和皮下组织感染风险。
  • 对于皮肤感染高危患者,应谨慎使用托珠单抗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To examine the risk of serious infections (SIs) among patients with rheumatoid arthritis (RA) treated with tocilizumab compared with tumor necrosis factor inhibitor (TNFi) in Korea. METHODS: We conducted a retrospective cohort study using the Korean National Health Insurance data. The study cohort included patients ≥18 years with RA who were initiated with tocilizumab or TNFi between January 2013 and June 2018. The primary outcome was a composite endpoint of SIs, defined as an infection resulting in intravenous antimicrobial therapy or hospitalization. Secondary outcomes were organ-specific SIs. To control for confounders, we used inverse probability of treatment weighting (IPTW) using propensity score. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using a multivariable Cox regression model. RESULTS: A total of 8794 patients were identified: 1395 and 7399 patients initiated with tocilizumab and TNFi, respectively. The mean follow-up durations were 1.2 years for tocilizumab initiators and 1.0 year for TNFi initiators. After IPTW and adjustment, no increased risk of SIs was observed in tocilizumab versus TNFi (HR, 1.00; 95%CI, 0.90-1.11). In the secondary analysis, tocilizumab was associated with a higher risk of skin and subcutaneous tissue infections (HR, 1.26; 95%CI, 1.02-1.54) and a lower risk of urological and gynecological infections (HR, 0.65; 95%CI, 0.49-0.87) compared to TNFi. CONCLUSION: In this population-based cohort of RA patients in Korea, tocilizumab was not associated with a higher risk of SI compared to TNFi. However, tocilizumab should be carefully used for patients at high risk for skin-related infections.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Jeon HL, Kim SC, Park SH, et al. The risk of serious infection in rheumatoid arthritis patients receiving tocilizumab compared with tumor necrosis factor inhibitors in Korea. Semin Arthritis Rheum. 2021. PMID: 34403814. doi:10.1016/j.semarthrit.2021.07.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。